

~Dupixent~ Prior Authorization Request Form

In order for members to receive Medicaid coverage for medications that require prior authorization, the prescriber must fax this form to Change Healthcare. Please complete this form in its entirety, and sign and date below. Incomplete requests will be returned for additional information. For questions, please contact the Change Healthcare Helpdesk at 1-844-679-5363.

Submit request via Fax: 1-844-679-5366

Prescribing physician:		Ben	Beneficiary:			
Name		Nan	Name:			
NPI:		Med				
Specia	lty:	Date	e of Birth:	Sex:		
Phone	#:	Pati	ent's Phone:			
Fax#: _		Pha	rmacy Name:			
Address: Contact Person at Office:		Pha	rmacy NPI:			
		Phai	macy Phone:	Pharmacy Fax:		
The fo	llowing MUST be complete	d for MEDICAL BENEFIT re	quests:			
HCPCS	J-code or other code:					
			NPI#	Medicaid ID#		
Dose:	Frequen	cv:		Patient weight (kg):		
	lation: □ prefilled syringe □					
	 Moderate to Severe Pers Chronic Rhinosinusitis with Prurigo Nodularis Prate to Severe Persistem Is the member currently set in the prescriber an allerging 	th Nasal Polyps t Asthma moking? NO □ YES □ Q	□ Eos uit Date (if applic	aderate to Severe Atopic Dermatitis sinophilic Esophagitis able) YES □		
0	ICS/LABA combination pro	ICS/LABA combination product trialed for a minimum of 3 consecutive months:				
	Specific Drug:	Response to therap	-	Dates of use:		
0	Does the patient have und at least one a week): NO I	YES D Number of d	aytime symptom	curring almost daily or waking at night with asthma occurrences per week: n occurrences per week:		
0	Has the patient had 2 or more exacerbations in the previous year despite use of medium-high dose ICS/LABA: NO I YES					
0	Does the patient have an e Eosinophil Count: Is the patient dependent o	Date obtained:		eatment blood eosinophil count? NO 🗆 YES 🗆		
-						





Renewal Requests for Moderate to Severe Persistent Asthma

(Clinical notes documenting member's response to therapy <u>must</u> be submitted):

- \circ Has the patient continued to receive therapy with an ICS/LABA? NO \Box YES \Box
- \circ Does the patient have documented improvement in FEV1 from baseline? NO \Box YES \Box
- \circ Does the patient have a decreased frequency of exacerbations? NO \square YES \square
- Is there documented evidence of a decreased dose/frequency of <u>oral steroid</u> requirements? **NO** □ **YES** □
- Is there documented evidence of a decreased dose/frequency of <u>rescue</u> medications? **NO** □ **YES** □

Moderate to Severe Atopic Dermatitis

- Is prescription written in consultation with a dermatologist, allergist, or immunologist? NO □ YES □
- \circ $\:$ Is at least 10% of the body's surface area is involved? NO \Box $\:$ YES \Box
- Has the patient trialed one moderate to high potency topical corticosteroid and topical calcineurin inhibitor within the last 6 months? NO □ YES □

Therapy:	Specific Drug:	Reason for discontinuation:	Date:
Topical Corticosteroid:			
Topical Calcineurin Inhibitor:			

• Renewal requests: please include clinical notes documenting response to therapy

Chronic Rhinosinusitis with Nasal Polyps:

- Is the prescriber an allergist or ENT Specialist: NO □ YES □
- Has the patient had at least a 3-month trial of 2 different nasal corticosteroids? NO □ YES □

Specific Drug:	Reason for discontinuation:	Date:
Has the nationt had a trial of a	at least a 10–14 day course of oral	

- O Has the patient had a trial of at least a 10−14 day course of oral corticosteroids? NO □ YES □
- \circ $\;$ Will the patient continue therapy with an intranasal corticosteroid? NO $\square\;$ YES $\square\;$
- Renewal requests: the patient must continue to receive therapy with an intranasal corticosteroid AND there must be documented improvement in nasal symptoms (please include clinical notes documenting response to therapy)

Prurigo Nodularis

- Is prescription written in consultation with a dermatologist, allergist, or immunologist? NO □ YES □
- Has the patient had at least a 1-month trial of a moderate to high potency topical corticosteroid and topical calcineurin inhibitor within the last 6 months?
 NO □ YES □
 Therapy: Specific Drug: Reason for discontinuation: Date:
 Topical Corticosteroid:

Topical Calcineurin Inhibitor:	

• Renewal requests: please include clinical notes documenting response to therapy



VERM	ONIT					
	ent of Vermont Health Access					
•	uth, 280 State Drive					
	y, Vermont 05671-1010					
	nilic Esophagitis:					
•						
0	 Has the diagnosis been confirmed by endoscopic esophageal biopsy showing ≥ 15 intraepithelial eosinophil high-power field NO □ YES □ Has the patient had a trial of at least 8 weeks for one of the following? NO □ YES □ 					
0						
	Therapy:	Specific Drug:	Reason for discontinuation:	Date:		
	Swallowed topical corticosteroid:					
	High-dose proton pump inhibitor:					
0	Renewal requests: please include	clinical notes documentin	g response to therapy			

By completing this form, I hereby certify that the above request is true, accurate and complete. That the request is medically necessary, does not exceed the medical needs of the member, and is clinically supported in your medical records. I also understand that any misrepresentations or concealment of any information requested in the prior authorization request may subject me to audit and recoupment.

Prescribers Signature:

Date:

